FLECAINIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H20F6N2O3
Molecular Weight	414.3434
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C1CCNC(C1)CN=C(c2cc(ccc2OCC(F)(F)F)OCC(F)(F)F)O

InChI

InChIKey=DJBNUMBKLMJRSA-UHFFFAOYSA-N

InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB01195
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/flecainide.html

Flecainide is a potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics. Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. Flecainide is sold under the trade name Tambocor (manufactured by 3M pharmaceuticals). Flecainide went off-patent on February 10, 2004. In addition to being marketed as Tambocor, it is also available in generic version and under the trade names Almarytm, Apocard, Ecrinal, and Flécaine.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Sodium channel protein type V alpha subunit 47 Target ID: CHEMBL1980 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21194571	Inhibitor 7728	67.2 µM [IC50]
Sodium channel protein type IV alpha subunit 23 Target ID: CHEMBL2072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20590641	Inhibitor 7728	18.0 µM [Ki]
HERG 89 Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26159617	Inhibitor 7728	1.49 µM [IC50]
Voltage-gated potassium channel subunit Kv4.3 7 Target ID: CHEMBL1964 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12875427	Inhibitor 7728	7.8 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Paroxysmal atrial fibrillation 2 Sources: https://www.drugs.com/pro/flecainide.html	Preventing		Approved 8043	Flecainide Approved Use In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening. Launch Date 9.9645122E11
Documented ventricular arrhythmias 2 Sources: https://www.drugs.com/pro/flecainide.html	Preventing		Approved 8043	Flecainide Approved Use In patients without structural heart disease, Flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician, are lifethreatening. Launch Date 9.9645122E11

C_max

Value	Dose	Co-administered	Analyte	Population
355 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1710 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
5979 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6238 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/3094570	2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.9 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1782978	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	FLECAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1782978	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		FLECAINIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
60% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/6364769			FLECAINIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	Disc. AE: Unconsciousness, Cyanosis... AEs leading to discontinuation/dose reduction: Unconsciousness Cyanosis Bradycardia Arrhythmia Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
3800 mg single, oral Overdose Dose: 3800 mg Route: oral Route: single Dose: 3800 mg Co-administed with:: diazepam, p.o(50 mg) loperamide, p.o(20 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	Disc. AE: Polymorphic ventricular tachycardia... AEs leading to discontinuation/dose reduction: Polymorphic ventricular tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/3107447
10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	healthy, 36 n = 1 Health Status: healthy Age Group: 36 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	Disc. AE: Ventricular tachycardia, Hypotension... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Hypotension Cardiopulmonary arrest Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423
1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: lamotrigine, p.o quetiapine, p.o Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Atrial fibrillation Age Group: 62 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	Disc. AE: Brugada syndrome, Mental status changes... AEs leading to discontinuation/dose reduction: Brugada syndrome Mental status changes Fatigue Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Condition: Paroxysmal supraventricular tachycardias\|paroxysmal atrial fibrillation/flutter\|Sustained ventricular tachycardia Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	Disc. AE: Ventricular tachycardia, Cardiac arrest... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Cardiac arrest Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display

AEs

AE	Significance	Dose	Population
Arrhythmia	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
Bradycardia	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
Cyanosis	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
Unconsciousness	Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487	healthy, 18 n = 1 Health Status: healthy Age Group: 18 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/20562156 Page: p.487
Polymorphic ventricular tachycardia	Disc. AE	3800 mg single, oral Overdose Dose: 3800 mg Route: oral Route: single Dose: 3800 mg Co-administed with:: diazepam, p.o(50 mg) loperamide, p.o(20 mg) Sources: https://pubmed.ncbi.nlm.nih.gov/3107447	healthy, 28 n = 1 Health Status: healthy Age Group: 28 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3107447
Cardiopulmonary arrest	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	healthy, 36 n = 1 Health Status: healthy Age Group: 36 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423
Hypotension	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	healthy, 36 n = 1 Health Status: healthy Age Group: 36 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423
Ventricular tachycardia	Disc. AE	10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423	healthy, 36 n = 1 Health Status: healthy Age Group: 36 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9825278 Page: p.423
Brugada syndrome	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: lamotrigine, p.o quetiapine, p.o Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Atrial fibrillation Age Group: 62 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1
Fatigue	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: lamotrigine, p.o quetiapine, p.o Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Atrial fibrillation Age Group: 62 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1
Mental status changes	Disc. AE	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Co-administed with:: lamotrigine, p.o quetiapine, p.o Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Atrial fibrillation Age Group: 62 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/27884575 Page: p.1
Cardiac arrest	Disc. AE	200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Condition: Paroxysmal supraventricular tachycardias\|paroxysmal atrial fibrillation/flutter\|Sustained ventricular tachycardia Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display
Ventricular tachycardia	Disc. AE	200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	unhealthy Health Status: unhealthy Condition: Paroxysmal supraventricular tachycardias\|paroxysmal atrial fibrillation/flutter\|Sustained ventricular tachycardia Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1604	substrate 1118 inhibitor 1702	inhibitor 1475

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT2 594	CYP1A2 972

Drug as perpetrator

Target	Modality	Activity
CYP2D6 1738	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/8801060/	yes [IC50 0.44 uM]
CYP2C9 1648	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/8801060/	yes [IC50 0.49 uM]
OCT2 595	inhibitor 3045 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 191 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 972	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/	yes
CYP2D6 1118	substrate 3113 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/	yes		yes (co-administration study) Comment: During the period in which the CYP2D6 inhibitor paroxetine was administered, the flecainide AUC in extensive and intermediate metabolizers was increased to 128.5% of basal values (90% CI, 122.2%– 135.2%) and 116.6% of basal values (90% CI, 107.3%–126.8%). However, poor metabolizers exhibited no alterations in AUC after administration of paroxetine (pharmacogenomic studies were also performed) Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732943/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1507	inhibitor 1489 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573407/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:75984	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:75984
ChemicalBook	CB0663265	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0663265
MolPort	MolPort-003-847-380	https://www.molport.com/shop/molecule-link/MolPort-003-847-380
eMolecules	901891	https://www.emolecules.com/cgi-bin/more?vid=901891

PubMed

Title	Date	PubMed
Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.	1986 Dec	3105568
Dysarthria and visual hallucinations due to flecainide toxicity.	1986 Jan	3099275
Flecainide acetate in the treatment of tachycardias associated with Mahaim fibres.	1987 Aug	3117552
[Hemodynamic effects of the anti-arrhythmia agent flecainide (Tambocor) in coronary surgery patients].	1987 Jun	3115131
[Drug-induced intrahepatic cholestasis caused by flecainide acetate and enalapril].	1987 Mar	3034817
Flecainide-induced sustained ventricular tachycardia successfully treated with lidocaine.	1987 Sep	3113836
Rapid suppression of flecainide-induced incessant ventricular tachycardia with high-dose intravenous amiodarone.	1988 Apr	3127126
[Central nervous system side effects due to anti-arrhythmia therapy. Psychotic depression due to flecainide].	1988 Mar 11	3127189
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group.	1989 Dec	2513143
Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol.	1989 Dec	2480856
Cardioprotective effects of various class I antiarrhythmic drugs in canine hearts.	1989 Jul	2738264
Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation.	1989 Jul 15	2500880
[Bidirectional tachycardia during therapy with lorajmine].	1989 Oct	2605577
Generalized seizures as the presentation of flecainide toxicity.	1989 Oct	2513205
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium].	1989 Sep	2510412
Torsades de pointe with flecainide-amiodarone therapy.	1990	2120306
Dangerous recurrence of arrhythmia following withdrawal of flecainide.	1990 Aug	2118487
Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs.	1990 Aug 1	2114784
Profound exacerbation of neuromuscular weakness by flecainide.	1990 Feb	2105626
Acute urinary retention associated with flecainide.	1990 Jan-Feb	2106405
Serious interactions of sotalol with amiodarone and flecainide.	1990 Mar 5	2123962
Amiodarone toxicity: myopathy and neuropathy.	1990 May	2158741
[Effects of oral flecainide treatment of refractory tachyarrhythmias].	1990 May	2115193
Combined application of class I antiarrhythmic drugs causes "additive", "reductive", or "synergistic" sodium channel block in cardiac muscles.	1990 Nov	2176934
Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.	1990 Sep 15	1975861
Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.	1991 Aug	1906902
Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group.	1991 Feb	1899432
Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia.	1991 Feb 1	1898629
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.	1991 Jan	1898640
Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide.	1991 Jan 15	1898998
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.	1991 Mar 21	1900101
The Relationship Between HIV Infection and Cardiovascular Disease.	2008 Aug	19936197
Drug therapy considerations in arrhythmias in children.	2008 Aug 1	18679519
ECGs in the ED.	2008 Nov	19018229
Role of cytochrome P450 in drug interactions.	2008 Oct 18	18928560
A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.	2009 Apr	19174378
Is flecainide dangerous in long QT-3 patients?	2009 Jan	19140927
Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.	2009 Jul	19531695
Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current.	2009 Jun	19498275
A case of flecainide-induced hyponatremia.	2009 Oct	19298558
Iatrogenic Flecainide toxicity.	2010 Dec	20736205
Tpeak-Tend interval and Tpeak-Tend/QT ratio as markers of ventricular tachycardia inducibility in subjects with Brugada ECG phenotype.	2010 Feb	19897501
Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.	2010 Mar 10	20219811
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release.	2011 Jul 10	21743453
Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.	2011 Jun	21641380
Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.	2011 Oct	21515356
Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.	2011 Sep	21693436
Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease.	2012 Oct	22700542
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.	2013 Dec	24052561
The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.	2013 Mar	23261645

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Ventricular Tachycardia Initial dose: 100 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved. Most patients with SUSTAINED VT do not require more than 150 mg every 12 hours (300 mg/day), and the maximum dose recommended is 400 mg/day. Usual Adult Dose for Atrial Fibrillation Initial dose: 50 mg orally every 12 hours. Maintenance dose: May be increased in increments of 50 mg bid every 4 days until efficacy is achieved.

Route of Administration: Oral

In Vitro Use Guide

Flecainide produced a dose-dependent prolongation of the cardiac action potential at 1 and 3uM in human pluripotent stem cell-derived cardiomyocytes.

Name

Type

Language

FLECAINIDE

Official Name

English

N-(2-PIPERIDYLMETHYL)-2,5-BIS(2,2,2-TRIFLUOROETHOXY)BENZAMIDE

Systematic Name

English

FLECAINIDE [VANDF]

Common Name

English

THN102 COMPONENT FLECAINIDE

Common Name

English

THN-102 COMPONENT FLECAINIDE

Code

English

FLECAINIDE [MI]

Common Name

English

FLECAINIDE [WHO-DD]

Common Name

English

NSC-719273

Code

English

FLECAINIDE [INN]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175426